Table 1

 Baseline patient characteristics

Dose reduction (n=121)Usual care (n=59)
General characteristics
Age (years)*59 (10.5)58 (9.3)
Female sex75 (62)41 (69)
Current smoking29 (24)18 (31)
Body mass index*27 (4.9)26 (4.0)
Diagnosis according to 2010 or 1987 ACR criteria114 (94)58 (98)
Disease duration (years)†10 (6-17)10 (6-16)
Rheumatoid factor positive94 (78)49 (83)
Anti-citrullinated peptide antibodies positive77 (64)39 (68)
Erosive disease99/116 (85)54 (92)
SvdH score†23 (6-50)17.5 (8.5-46.5)
Employed44 (36)21 (36)
Travel distance (one way) to hospital (km)†30.4 (13.5-47.2)33.2 (17.3-50)
Disease activity
No of swollen joints†0 (0-0)0 (0-1)
No of tender joints†0 (0-1)0 (0-0)
Erythrocyte sedimentation rate (mm/h)*17 (14)16 (10)
C reactive protein (mg/L)*4 (4)4 (4)
DAS28-CRP score*2.2 (0.6)2.1 (0.7)
DAS28-ESR score*2.5 (0.7)2.5 (0.8)
2011 ACR/EULAR Boolean based remission31 (26)21 (36)
Treatment
Etanercept/adalimumab79/42 (65/35)39/20 (66/34)
Duration of current TNF inhibitor treatment (years)*3.5 (2.5)3.6 (2.3)
Previous dose reduction attempt with current TNFi21 (17)11 (19)
Previous DMARD treatment†2 (1-3)2 (1-3)
Previous conventional synthetic DMARD combination treatment‡30/100 (30)22/49 (45)
Previous TNF inhibitor treatment†0 (0-1)0 (0-1)
Concomitant treatment
 DMARD 73 (60)47 (80)
 Methotrexate 58 (48)41 (69)
 Methotrexate dose (mg)*15.8 (5.7)16.1 (5.5)
 Glucocorticoids6 (5)3 (5)
 Non-steroidal anti inflammatory drugs65 (54)35 (59)

Data are number (%) of patients unless stated otherwise. ACR/EULAR=American College of Rheumatology/European League Against Rheumatism.

*Mean (standard deviation).

†Median (interquartile range).

‡In the dose reduction and usual care groups, 21 and 10 patients had missing values, respectively.